Nasal implant developer Intersect ENT Inc. blew away its IPO. The Menlo Park company's (NASDAQ: XENT) stock gained more than 17 percent in its first day on the market, finishing near the top of its IPO price range. One of the few initial public offerings by a life sciences company with an actual medical product for sale, Intersect sold 5 million shares at $11 each.
Comment on Intersect's first day on the market is nothing to sneeze at
Ron Leuty, Biz Journals
Thu, 07/24/2014 - 3:37pm
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more